IRONWOOD PHARMACEUTICALS INC
IRWDCIK 0001446847 · Pharmaceutical Preparations · Nasdaq
Revenue (TTM)
$354.95M
−60.9% YoY
Q1 Apr 2026
Net Income (TTM)
$67.07M
−105.7% YoY
Q1 Apr 2026
EPS Diluted (TTM)
$0.38
−104.3% YoY
Q1 Apr 2026
Gross Margin
94.9%
Q1 Apr 2026
Operating Margin
46.3%
Q1 Apr 2026
Net Margin
18.9%
Q1 Apr 2026
Free Cash Flow (TTM)
$150.11M
Q1 Apr 2026
Cash
$220.47M
Q1 Apr 2026
Total Debt
$320.21M
Q1 Apr 2026
Shares Outstanding
164.61M sh
Q1 Apr 2026
Revenue & Net Income
EPS (Diluted)
Margins
Cash Flow
Revenue Growth (YoY)
Balance Sheet
Cash vs Debt
Latest news
All news →-
Low Neutral
Ironwood Pharmaceuticals (IRWD) Increases Stock Award Pool to 26M Shares
The company raised its equity incentive plan's share reserve by 10 million shares, approved by stockholders in June.